Jaguar Health outlines dual NDA filing targets for late 2026 as clinical catalysts converge

Earnings Call Insights: Jaguar Health (JAGX) Q3 2025

MANAGEMENT VIEW

* Lisa Conte, Founder, CEO, President & Director, highlighted that combined net third quarter 2025 revenue of approximately $3.1 million for prescription and nonprescription products, including license revenue, increased approximately 4% versus net Q2 2025. Conte emphasized, "2025 continues to be the year of convergence of key clinical and regulatory catalysts for Jaguar. Catalysts that we feel will be transformative in terms of the value that they bring to all stakeholders in the company from patients...to shareholders."
* Conte described three key late-stage business development initiatives: orphan indications of crofelemer for intestinal failure (MVID and SBS), a cancer therapy-related diarrhea (CTD) program for a planned label extension of Mytesi, and the Canalevia animal health platform. She noted ongoing negotiations for licensing and development partnerships across these programs.
* Conte discussed recent clinical milestones, including crofelemer's reduction of parenteral support by up to 37% in MVID patients and 12% in SBS patients, presented at NASPGHAN. She stated, "No approved treatments exist for MVID, and we're not aware of any approach even in development for MVID."
* Carol Lizak, Chief Financial Officer, stated, "The combined net third quarter 2025 revenue of approximately $3.1 million for prescription and nonprescription products, including license revenue, increased approximately 4% versus net second quarter 2025 revenue of approximately $3 million and equaled net third quarter of 2024 revenue of approximately $3.1 million."

OUTLOOK

* Conte indicated that Jaguar's strategy continues to focus on negotiating business development partnerships for late-stage Human and Animal Health products to generate non-dilutive funding. She outlined timelines for regulatory filings: "Timeline associated with these activities for intestinal failure...having data that's fileable by potentially the end of 2026...looking next year for breakthrough designation in the United States and PRIME in Europe. For cancer therapy-related diarrhea, we would look to complete the trial for the randomized withdrawal by the end of 2026 as well in support of a supplemental NDA filing. So that would be two potential NDA filings from data at the end of 2026 on the Human side."
* Conte added, "On the Animal Health side, we're looking to close an animal health partnership in the very near future."

FINANCIAL RESULTS

* Carol Lizak reported that Mytesi prescription volume increased by approximately 0.9% in Q3 2025 over Q2 2025 but decreased by 3.6% compared to Q3 2024.
* Lizak stated, "Loss from operations decreased by $24,000 from $7.2 million in the third quarter of September 30, 2024, to $7.3 million during the same period this year. Non-GAAP recurring EBITDA for the third quarters of 2025 and 2024 were a net loss of $8.9 million and $9.2 million respectively. Net loss attributable to common shareholders decreased by $352,000 from $9.9 million...to $9.5 million in the same period in 2025."

Q&A

* NOT_APPLICABLE: No analyst Q&A segment was present in the transcript.

SENTIMENT ANALYSIS

* No analyst questions or comments were present; analyst sentiment cannot be assessed.
* Management maintained a positive and confident tone throughout, especially regarding clinical catalysts and business development. Conte expressed enthusiasm, stating, "We remain fully energized and excited about the multiple expected near-term catalysts for crofelemer in the company, all of which we view as significant value-enhancing and potentially transformative for patients and...all stakeholders...including our shareholders."
* Compared to the previous quarter, the tone remains upbeat and focused on the convergence of clinical and regulatory milestones, with continued emphasis on business development and nondilutive funding.

QUARTER-OVER-QUARTER COMPARISON

* Revenue increased slightly quarter-over-quarter, with Q3 2025 at approximately $3.1 million, up from $3 million in Q2 2025. Mytesi prescription growth slowed significantly from Q2's 6.5% sequential growth to 0.9% in Q3, and prescription volume declined year-over-year.
* Loss from operations and net loss attributable to common shareholders narrowed compared to the prior year, reversing the increase seen last quarter.
* Strategic focus continues on monetizing late-stage assets through partnerships and advancing clinical programs, with more specificity in regulatory timelines and anticipated filings by end of 2026.
* Management confidence remains strong; analysts' focus and sentiment cannot be compared due to lack of Q&A.

RISKS AND CONCERNS

* Management cited the ultra-rare nature and severity of MVID and short bowel syndrome, limited approved treatments, and the need for expedited regulatory pathways.
* The company is reliant on successful business development deals for nondilutive funding to advance late-stage programs.
* Regulatory approval timelines for key programs are ambitious and contingent on continued positive clinical data and successful negotiations.

FINAL TAKEAWAY

Jaguar Health's third quarter call highlighted incremental revenue growth and a strong focus on advancing late-stage clinical and regulatory milestones, particularly with crofelemer for orphan and cancer therapy-related indications. Management reiterated its commitment to nondilutive funding through strategic partnerships and signaled two potential NDA filings by the end of 2026, which could significantly impact the company's trajectory if achieved. The company remains confident in the value-enhancing potential of its pipeline, with several major catalysts anticipated in the near term.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/jagx/earnings/transcripts]

MORE ON JAGUAR HEALTH

* Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript [https://seekingalpha.com/article/4844611-jaguar-health-inc-jagx-q3-2025-earnings-call-prepared-remarks-transcript]
* Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4814967-jaguar-health-inc-jagx-q2-2025-earnings-call-transcript]
* Jaguar Health registers 2.62M shares for resale following private placements [https://seekingalpha.com/news/4501788-jaguar-health-registers-262m-shares-for-resale-following-private-placements]
* Seeking Alpha’s Quant Rating on Jaguar Health [https://seekingalpha.com/symbol/JAGX/ratings/quant-ratings]
* Historical earnings data for Jaguar Health [https://seekingalpha.com/symbol/JAGX/earnings]